Drug Type CAR-NK |
Synonyms allogeneic anti-BCMA CAR NK-cell therapy (Bellicum), iMC-BCMA.CAR-IL15-modified NK cells, iMC-BCMA.z-IL15 + [1] |
Target |
Action inhibitors |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | United States | 05 Nov 2020 |